9 results about "Angina" patented technology

The invention discloses an application of SNF2 protein derived from streptococcus angina extracellular vesicles in gastric cancer prognosis. The chromatin remodeling protein SNF2 derived from S.anginosus EVs can be combined with a transcription factor TEAD1, so that the transcription of the palmitoyl transferase ZDHHC11 is promoted together. Then, the stability of the ZDHHC11 is enhanced by catalyzing palmitoylation of PD-L1, and finally immune escape is induced. In addition, SNF2 also can activate AXL, CTGF, CYR61 and other carcinogenic targets at the downstream of TEAD1, thereby further accelerating the malignant progression of gastric cancer. In an in-vivo experiment, the intragastric administration of the S.anginosus EVs not only promotes the tumor growth of mice, but also significantly inhibits the infiltration of CD8 + T cells. Blocking of ZDHHC11 can effectively reverse immune escape, and has a synergistic effect with an anti-PD-1 therapy, so that the treatment effect is remarkably improved.

The application relates to application of lactococcus lactis in a composition for inhibiting streptococcus pyogenes and angina streptococcus and a product, and belongs to the field of microbial technology. The technical problem to be solved is to provide application of lactococcus lactis in preparation of a composition for inhibiting streptococcus pyogenes and angina streptococcus or treating tumors, and the technical solution points are that the lactococcus lactis is applied in preparation of the composition for inhibiting streptococcus pyogenes and angina streptococcus. The lactococcus lactis OA56 of the application can efficiently inhibit streptococcus pyogenes and angina streptococcus, has low ability of forming a biological membrane, shows strong adhesion to oral epithelial cells and hydroxyapatite, can effectively relieve clinical symptoms caused by streptococcus pyogenes infection, reduce inflammation reaction of gastric epithelial cells induced by angina streptococcus infection, and can treat or assist in treating angina streptococcus related tumors.

Provided are compositions comprising nicorandil compound(s) in a controlled release formulation that releases at least about 30% of the nicorandil compound(s) into the intestine of human subjects. Such compositions can include a gastric acid dissolution susceptible component (GADSC) and a gastric acid dissolution resistant component (GADRC), wherein upon maintaining the composition in contact with a pH 1.2 dissolution media for a period of about 2 hours (1) the GADRC releases a statistically significantly smaller proportion of the one or more nicorandil compounds in the GADRC than the proportion of one or more nicorandil compounds release from the GADSC and (2) the composition releases no more than 50% of the one or more nicorandil compounds contained in the composition. The invention further provides methods of product such compositions and therapeutic uses of compositions, e.g., comprising once-daily administration of the composition to treat one or more diseases or conditions, including angina.

The present invention relates to the use of bacterial compositions having an arginine deiminase activity (inhibition of nitric oxide synthase by conversion of L-arginine to L-citrulline) of 1-1,000 μmol L-citrulline / h / g composition and a sphingomyelinase (ceramide generation) activity of 0.01-1.000 nmoles ceramides / h / g composition in the treatment and / or prophylaxis of airway diseases caused by viruses such as influenza viruses, coronaviruses, as SARS-CoV, MERS-CoV and SARS-CoV-2, avian viruses, respiratory syncytial virus (VRS), rhinoviruses, pneumoviruses, or respiratory failure induced or aggravated by viral infections, angina pectoris, pulmonary heart, respiratory distress, pulmonary edema, neonatal asphyxia, myocardial infarction, heart failure, respiratory failure Pickwick syndrome, pulmonary hypertension, pneumonia or even cystic fibrosis (CF) aggravated by viral infections.

A method for reducing a composite endpoint risk of myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death in a subject including administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), wherein the patient has at least one history of diabetes, a past myocardial infarction, an unstable angina, a coronary bypass surgery, and a coronary angioplasty; wherein the patient is also administered a daily dose of statin therapy; and wherein the composite endpoint risk in the subject is reduced relative to a dosing regimen where the patient receives standard secondary prevention therapy of a statin.

The application discloses a quality detection method for active ingredients of a traditional Chinese medicine compound for dredging blood vessels and reducing blood sugar by using UPLC-Q / TOF-MS, and has the advantages of comprehensive detection components, high sensitivity and simple operation. 186 chemical components are identified, including 45 terpene components, 41 glycoside components, 19 organic acid components, 18 flavone components, 10 alkaloid components, 6 sugar components and 47 other components. The detection method can be applied to internal quality control standards, chemical component identification and intermediate component detection of the traditional Chinese medicine compound for dredging blood vessels and reducing blood sugar.

The external Chinese herbal medicine essential oil combined liquid medicine is characterized by being prepared from the following Chinese herbal medicine essential oil: rhizoma arisaematis, radix zanthoxyli, semen strychni, radix aconiti carmichaeli, herba ephedrae, kadsura pepper stem, rhizoma corydalis, pogostemon cablin, ligusticum wallichii, ginger, radix cynanchi paniculati, artemisia anomala, radix angelicae, melissa officinalis, cinnamon, mint and safflower carthamus. The traditional Chinese medicine has the effects of relaxing tendons and activating collaterals, promoting blood circulation to remove blood stasis and relieving swelling and pain; the traditional Chinese medicine composition has the effects of being high in medicine efficacy permeability, rapid in effect taking and capable of rapidly relieving the illness state, and can be used for preparing external application for treating diabetic eye diseases and heart diseases such as heart diseases, coronary heart diseases, heart discomfort or pain, stuffiness pain, angina pectoris, neck arteriosclerosis, plaques and static arterial thrombosis in cardiovascular and cerebrovascular diseases. The external medicine is used for relieving swelling and pain, soothing channels and activating collaterals, and promoting blood circulation to remove blood stasis. The invention provides a convenient, rapid and effective external medicine treatment mode for patients with the diseases.

A method for reducing a composite endpoint risk of myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death in a subject including administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), wherein the patient has at least one history of diabetes, a past myocardial infarction, an unstable angina, a coronary bypass surgery, and a coronary angioplasty; wherein the patient is also administered a daily dose of statin therapy; and wherein the composite endpoint risk in the subject is reduced relative to a dosing regimen where the patient receives standard secondary prevention therapy of a statin.

The present invention provides compounds of formula (I) which act as a calcium channel blocker, for use in the prevention and / or treatment of diseases associated with dysfunction of the calcium channels and / or imbalance in intracellular calcium homeostasis, such as hypertension, Raynaud's disease, migraine, migraine prophylaxis, viral infections, angina, arrhythmias, subarachnoid hemorrhage, hypertrophic cardiomyopathy, esophageal spasm, and pulmonary hypertension, as well as a composition and a pharmaceutical composition comprising said compounds.